Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Halogenated phenols + Phenol
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 7 · 1991–2026
Showing the 50 most relevant studies, sorted by most relevant.
Ludmila Martínková, M. Kotik, E. Markova, et al.
Chemosphere, 2016
L. Hovander, T. Malmberg, M. Athanasiadou, et al.
Archives of Environmental Contamination and Toxicology, 2002
M. T. Cronin, T. Wayne Schultz
Chemosphere, 1996
H.S. Joglekar, S.D. Samant, J.B. Joshi
Water Research, 1991
Shafi Kuttiyathil M, Ali L, Altarawneh M
2025
Handling the waste associated with halogenated polymers is a daunting task due to the well-documented emission of halogen-bearing toxicants during the disposal or recycling operation. According to the Stockholm Convention treaty, most of these products are classified as persistent organic pollutants due to their potential health hazards. This review aims to provide a holistic overview of the recent updates for treating halogenated polymeric waste through physical, chemical and biological approaches. In the line of inquiry, critical analysis of the obstacles and prospects associated with each degradation technique on the halogenated polymer has been performed, assessing based on the degradation efficiency, treatment upscaling, pollution control, and feasibility. Though many treatments show promising results, they also entail drawbacks. Thermal treatment exploiting various metal oxides, especially calcium additives, is considered the most executable technique for halogenated polymer valorization coupled with mineralization/metal extraction due to its intuitive operational feasibility and potential scalability. Strategies for combating the soaring halogenated polymeric wastes summarized herein tap into promoting a circular economy approach for their sustainable disposal and recycling.
Abstract licence: CC BY
L. Rucká, J. Nešvera, M. Pátek
World Journal of Microbiology and Biotechnology, 2017
J. Nešvera, L. Rucká, M. Pátek
Advances in applied microbiology, 2015
T. Zhao, Q. Chen
2016
K. Liu, Junhe Lu, Yuefei Ji
Water research, 2015
Yu Zhou, Zhipan Ma, Junjie Tang, et al.
Nature Communications, 2018
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.